Plain-English translation of NCT07775508 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new immunotherapy called SL1617 for patients with B-cell lymphoma that has relapsed (come back) or become resistant to standard treatments. SL1617 works by using your body's own immune cells—specifically T cells and NK cells—and engineering them to recognize and attack cancer cells. The trial is designed to find out how safe this treatment is and what dose works best.
Many patients with B-cell lymphoma eventually develop cancer that no longer responds to standard chemotherapy or antibody treatments, leaving few options. This medication attempts to harness the power of the immune system in a new way—by directly modifying your cells inside your body—to fight cancer that has become resistant to conventional approaches.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous infusion of the medication—just one injection into your vein. The study will start with a small dose in the first group of participants, then increase the dose in later groups to find the safest and most effective level. You will be closely monitored for side effects and your response to treatment, likely through regular clinic visits and blood tests. The trial is designed to enroll 18 patients total, and researchers will carefully watch how your body and immune system respond over time.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
China